The most credible disease-modifying model is that trazodone must reach a higher exposure range, likely around 150-200 mg/day, to engage the PERK-eIF2alpha integrated stress response in neurons and restore translation. This remains a mechanistically grounded but unvalidated human threshold derived mainly from preclinical tauopathy/prion data and supported by the observation that many real-world dementia prescriptions were likely below this range.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["Target Gene: EIF2AK3 EIF2S1 ATF4 DDIT3"]
B["Molecular Mechanism Pathway Activation"]
C["Cellular Phenotype Neuronal / Glial Response"]
D["Network Effect Circuit-Level Consequence"]
E["Disease Relevance Neurodegeneration Link"]
A --> B --> C --> D --> E
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style E fill:#1b5e20,stroke:#81c784,color:#81c784
Median TPM across 13 brain regions for EIF2AK3; EIF2S1; ATF4; DDIT3 from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
7 citations7 with PMIDValidation: 0%4 supporting / 3 opposing
✓For(4)
No supporting evidence
No opposing evidence
(3)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
3
1
MECH 3CLIN 3GENE 0EPID 1
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Trazodone rescued neurodegeneration and reversed e…
Trazodone rescued neurodegeneration and reversed eIF2alpha-P-linked translational repression in mouse prion an…▼
Trazodone rescued neurodegeneration and reversed eIF2alpha-P-linked translational repression in mouse prion and tauopathy models, with authors mapping efficacious exposure to a clinically relevant human dose estimate.
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF patients with Alzheimer's disease are randomized to receive trazodone 150–200 mg/day for 12 weeks THEN a measurable reduction in cerebrospinal fluid phosphorylated eIF2α (p‑eIF2α) levels will be observed compared to those receiving <100 mg/day.
pendingconf: 0.55
Expected outcome: CSF p‑eIF2α concentration decreases by ≥20 % (or falls below the assay’s lower limit of quantification) in the high‑dose group relative to the low‑dose group after 12 weeks of treatment.
Falsified by: No statistically significant difference in CSF p‑eIF2α levels between the high‑dose and low‑dose groups after 12 weeks (p > 0.05).
Method: Multi‑center, randomized, open‑label controlled trial comparing high‑dose (150–200 mg/day) versus low‑dose (<100 mg/day) trazodone in mild‑to‑moderate Alzheimer’s disease; CSF collected via lumbar puncture at baseline and week 12; biomarker analysis performed blinded to treatment allocation.
IF individuals with prodromal or mild dementia are treated with trazodone 150–200 mg/day for 12 months THEN their annual decline in global cognition (as measured by change in MMSE score) will be at least 2 points less than that of matched patients receiving <100 mg/day.
pendingconf: 0.50
Expected outcome: High‑dose trazodone group shows an average MMSE decline of ≤2 points over 12 months, whereas the low‑dose group declines ≥4 points.
Falsified by: The high‑dose group exhibits an MMSE decline equal to or greater than the low‑dose group (no protective effect), indicating no dose‑dependent disease‑modifying benefit.
Method: Prospective, propensity‑score‑matched cohort study of community‑dwelling older adults with mild cognitive impairment or mild dementia initiating trazodone at either high (150–200 mg/day) or low (<100 mg/day) doses; cognitive testing (MMSE) performed at baseline, 6 months, and 12 months; adverse events and comorbidities recorded.
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬
EIF2AK3; — Search for structure
Click to search RCSB PDB